Pancreatic ductal adenocarcinoma (PDAC) represents a malignancy characterized by one of the lowest survival rates; furthermore, at the time of diagnosis, the majority of tumors are deemed unresectable. Consequently, there exists a pressing need to investigate early signs and symptoms, as well as to implement screening protocols for patients at risk of developing PDAC. By doing so, we may enhance the potential for improved treatment outcomes in light of the typically poor prognosis associated with PDAC. A review of recent literature focused on symptoms that manifest prior to the diagnosis of PDAC has been conducted, emphasizing the underlying biological mechanisms and potential screening applications, alongside data pertaining to the influence of these symptoms on prognosis and treatment. Additionally, the roles of pre-existing pain, depression, diabetes mellitus, and paraneoplastic syndromes in treatment and outcomes were scrutinized to ascertain the feasibility of integrating these factors into clinical practice.
胰腺导管腺癌（PDAC）是一种生存率极低的恶性肿瘤，且多数患者在确诊时已无法进行手术切除。因此，亟需探究PDAC的早期症状与体征，并对高危人群实施筛查策略，以期改善该疾病通常不良的预后，提升治疗成效。本文综述了近期关于PDAC确诊前出现症状的相关研究，重点探讨了其潜在的生物学机制及筛查应用价值，同时分析了这些症状对预后和治疗的影响数据。此外，研究还评估了既存疼痛、抑郁、糖尿病及副肿瘤综合征在治疗与预后中的作用，以确定将这些因素纳入临床实践的可行性。
肿瘤(癌症)患者之家